The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 27, 2019

Filed:

Oct. 02, 2014
Applicant:

Nitto Denko Corporation, Osaka, JP;

Inventors:

Masahiro Fukasaka, Osaka, JP;

Mitsuhiko Hori, Osaka, JP;

Katsuyuki Okubo, Osaka, JP;

Daisuke Asari, Osaka, JP;

Arimichi Okazaki, Osaka, JP;

Eiji Kiyotoh, Osaka, JP;

Kyohei Matsushita, Osaka, JP;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 39/15 (2006.01); A61K 39/09 (2006.01); A61K 39/12 (2006.01); A61K 39/13 (2006.01); A61K 39/145 (2006.01); C12N 7/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A61K 39/00 (2013.01); A61K 39/0005 (2013.01); A61K 39/092 (2013.01); A61K 39/12 (2013.01); A61K 39/13 (2013.01); A61K 39/145 (2013.01); A61K 39/15 (2013.01); C12N 7/00 (2013.01); A61K 2039/52 (2013.01); A61K 2039/525 (2013.01); A61K 2039/541 (2013.01); A61K 2039/542 (2013.01); A61K 2039/543 (2013.01); A61K 2039/544 (2013.01); A61K 2039/55572 (2013.01); C12N 2710/20034 (2013.01); C12N 2720/12334 (2013.01); C12N 2760/16034 (2013.01); C12N 2770/32634 (2013.01);
Abstract

The present disclosure relates to a method for inducing humoral immunity in a human or animal, that includes administering to the human or animal a mucosal vaccine composition to a mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane. The mucosal vaccine composition includes at least one antigen derived from a pathogen; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of, and, or a salt of the lipopolysaccharide, wherein the mass ratio between a total mass of the adjuvant and a total mass of the antigen is 0.002 to 500. The mucosal vaccine composition is administered in an amount effective to induce humoral immunity in the human or animal.


Find Patent Forward Citations

Loading…